Interpretation and Recommended Testing for Antiphospholipid Antibodies

Monica Galli

doi:10.1055/s-0032-1304716

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2012; 38(04): 348-352
DOI: 10.1055/s-0032-1304716

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Interpretation and Recommended Testing for Antiphospholipid Antibodies

Monica Galli

¹Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy

› Institutsangaben

Abstract

The antiphospholipid syndrome (APS) is defined by the association of arterial and/or venous thrombosis and/or pregnancy complications with the presence of at least one of the main laboratory-detected antiphospholipid antibodies (aPL) (i.e., lupus anticoagulants [LA], IgG and/or IgM anticardiolipin antibodies [aCL], and IgG and/or IgM anti-β₂-glycoprotein I antibodies [aβ₂GPI]). During the last decade efforts have been made to improve the harmonization and reproducibility of laboratory detection of aPL and guidelines have been published. The prognostic significance of aPL is being clarified through the fine elucidation of their antigenic targets and pathogenic mechanisms. Several clinical studies have consistently reported that LA is a stronger risk factor for both arterial and venous thrombosis compared with aCL and aβ₂GPI. In particular, LA activity dependent on the first domain of β₂-glycoprotein I and triple aPL positivity are prognosticators of the thrombotic and obstetric risks. Hopefully, this increasing knowledge will help improve diagnostic and treatment strategies for APS.

Keywords

antiphospholipid syndrome - thrombosis - abortion - antiphospholipid antibodies

Volltext

Referenzen

References
1 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
2 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
3 Tincani A, Filippini M, Scarsi M, Galli M, Meroni PL. European attempts for the standardisation of the antiphospholipid antibodies. Lupus 2009; 18 (10) 913-919
4 Tincani A, Allegri F, Balestrieri G , et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114 (5–6) 553-558
5 Wong RCW, Gillis D, Adelstein S , et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 36 (1) 63-68
6 Reber G, Schousboe I, Tincani A , et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88 (1) 66-73
7 Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC ; European Forum on Antiphospholipid Antibodies Standardization Group. Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94 (3) 665-672
8 Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC ; Standardization group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2 (10) 1860-1862
9 Cervera R, Font J, Tincani A, Boffa MC. V meeting of the European forum on antiphospholipid antibodies. Autoimmun Rev 2006; 5 (7) 499-507
10 Pengo V, Biasiolo A, Gresele P , et al; Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5 (5) 925-930
11 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87 (11) 4120-4124
12 Galli M, Comfurius P, Maassen C , et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335 (8705) 1544-1547
13 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336 (8708) 177-178
14 de Laat BH, Derksen RHWM, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 2006; 107 (5) 1916-1924
15 de Laat BH, Derksen RHWM, Ubanus R, Roest M, de Groot P. β2GPI-dependent lupus anticoagulant activity highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602
16 de Laat BH, Derksen RHWM, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (4) 1540-1545
17 Banzato A, Pozzi N, Frasson R , et al. Antibodies to domain I of β(2)Glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011; 128 (6) 583-586
18 Simmelink MJ, Derksen RHW, Arnout J, De Groot PG. A simple method to discriminate between β2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1 (4) 740-747
19 Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2 (5) 702-707
20 Devreese KM. A functional coagulation test to identify anti-β2-glycoprotein I dependent lupus anticoagulants. Thromb Res 2007; 119 (6) 753-759
21 Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997; 77 (3) 486-491
22 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66 (6) 629-632
23 Horbach DA, van Oort E, Derksen RHWM, de Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity—discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79 (4) 790-795
24 Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86 (2) 617-623
25 Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-β2-glycoprotein I autoantibodies. Thromb Haemost 1999; 81 (2) 256-258
26 Pengo V, Banzato A, Bison E, Denas G, Padayattil Jose S, Ruffatti A. Antiphospholipid syndrome: critical analysis of the diagnostic path. Lupus 2010; 19 (4) 428-431
27 Galli M. The antiphospholipid triangle. J Thromb Haemost 2010; 8 (2) 234-236
28 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
29 Galli M, Luciani D, Bertolini G, Barbui T. Anti-β 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (8) 2717-2723
30 Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33 (11) 2214-2221
31 Previtali S, Barbui T, Galli M. Anti-β2-glycoprotein I and anti-prothrombin antibodies in antiphospholipid-negative patients with thrombosis: a case control study. Thromb Haemost 2002; 88 (5) 729-732
32 Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93 (6) 1147-1152
33 Ruffatti A, Tonello M, Del Ross T , et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96 (3) 337-341
34 Pengo V, Ruffatti A, Legnani C , et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8 (2) 237-242
35 Pengo V, Ruffatti A, Legnani C , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicentre prospective study. Blood 2011; 118: 4714-4718
36 Lee EY, Lee CK, Lee TH , et al. Does the anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis?. Thromb Res 2003; 111 (1–2) 29-32
37 Male C, Foulon D, Hoogendoorn H , et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106 (13) 4152-4158
38 Forastiero R, Martinuzzo M, Pombo G , et al. A prospective study of antibodies to β2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3 (6) 1231-1238
39 de Laat B, Pengo V, Pabinger I , et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7 (11) 1767-1773